Cargando…
Persistent SARS-CoV-2–specific immune defects in kidney transplant recipients following third mRNA vaccine dose
Kidney transplant recipients (KTRs) show poorer response to SARS-CoV-2 mRNA vaccination, yet response patterns and mechanistic drivers following third doses are ill-defined. We administered third monovalent mRNA vaccines to n = 81 KTRs with negative or low-titer anti-receptor binding domain (RBD) an...
Autores principales: | Werbel, William A., Karaba, Andrew H., Chiang, Teresa Po-Yu, Massie, Allan B., Brown, Diane M., Watson, Natasha, Chahoud, Maggie, Thompson, Elizabeth A., Johnson, Aileen C., Avery, Robin K., Cochran, Willa V., Warren, Daniel, Liang, Tao, Fribourg, Miguel, Huerta, Christopher, Samaha, Hady, Klein, Sabra L., Bettinotti, Maria P., Clarke, William A., Sitaras, Ioannis, Rouphael, Nadine, Cox, Andrea L., Bailey, Justin R., Pekosz, Andrew, Tobian, Aaron A.R., Durand, Christine M., Bridges, Nancy D., Larsen, Christian P., Heeger, Peter S., Segev, Dorry L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037915/ https://www.ncbi.nlm.nih.gov/pubmed/36966905 http://dx.doi.org/10.1016/j.ajt.2023.03.014 |
Ejemplares similares
-
Heterologous versus homologous boosting elicits qualitatively distinct, BA.5–cross-reactive T cells in transplant recipients
por: Thompson, Elizabeth A., et al.
Publicado: (2023) -
A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response
por: Karaba, Andrew H., et al.
Publicado: (2022) -
Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination
por: Chiang, Teresa PY, et al.
Publicado: (2022) -
SARS-CoV-2 antibody testing for transplant recipients: A tool to personalize protection versus COVID-19
por: Werbel, William A., et al.
Publicado: (2022) -
Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
por: Karaba, Andrew H., et al.
Publicado: (2023)